steadymed therapeutics skip to navigation our leadership back to leadership peter d noymer phd evp of research  development and cto peter has over  years of drug delivery combination product development through to commercialization he is responsible for developing and advancing the companys pipeline and leading product development and clinical and regulatory affairs previously he was vp of product rd at alexza pharmaceuticals where he worked on several development programs on combination products for novel therapies including adasuve® the first fda approved inhalable treatment for acute agitation prior to that he held management positions at aradigm corporation and was a visiting assistant professor at carnegie mellon university peter noymer  steadymed ltd  zoominfocom peter d noymers involvement in venture capital via alexza pharmaceuticals inc aradigm corp steadymed therapeutics inc want to see morewant to find out who got funded and who’s funding the next big thing in real time all across the world tailored to your specific areas of focus deals per dayget access to the most exhaustive worldwide funding watch on the webcomprehensive funding informationknow about who invested in a company which sites covered the event the funding history etcexclusive insightsview original analytics such as most dynamic industries most active investors and morestay awareget emailed when deals critical to your business happen filter by region industry and topics of interestas seen onhave a loginsign inregister nowits freeuse your social accountor fill in the quick formregister nowpromise we wont spamsign invia your social accountvia your existing wgf accountremember meregister its freeforgot your passwordsign inforgot your passwordenter your email and we will send you your new passwordreset passwordthe worlds largest funding basepeoplepeterdnoymersectionpeoplesubsectiondetailid search deals by company name industry location investors search peterd noymerget alertedif peter d noymer gets fundedpeter d noymeralexza pharmaceuticals inc  vp of product rdaradigm corp  held management positionssteadymed therapeutics inc  evp of rd  ctodeals involving peter d noymer raised with alexza pharmaceuticals inc on march  raised with alexza pharmaceuticals inc on july 0 raised with alexza pharmaceuticals inc on may 07 raised with alexza pharmaceuticals inc on october 0undisclosed raised with alexza pharmaceuticals inc on august 0 raised with aradigm corp on may 08 raised with aradigm corp on june 00 raised with steadymed therapeutics inc on march  raised with steadymed therapeutics inc on june 0 raised with steadymed therapeutics inc on september please note that all data is automatically extracted and errors can occurthe whogotfunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and completesome of the profile information was collected using the crunchbase api for more details on the profile please check peter d noymer on crunchbaseinaccurate data help us improve whogotfunded post a comment peter d noymer  executive vice president of research  development  chief technical officer at steadymed ltd news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink peter d noymer executive vice president of research  development  chief technical officer at steadymed ltd overview in the news relationships paths education career history peter d noymer executive vice president of research  development  chief technical officer at steadymed ltd overview age  born 7 number of relationships this person is connected to  people in the news see more marketline newswire january   cardiome and steadymeds maa for pah treatment receives ema approval pr newswire january   cardiome and steadymed announce decision for centralized review of trevyent® by the european medicines agency san jose mercury news california august   four newcomers will challenge mayor in the race for town council relationships see details jonathan m n rigby president chief executive officer  director at steadymed therapeutics inc robert zwolinski vice president operations at steadymed therapeutics inc marylyn rigby directormarketing  business development at steadymed therapeutics inc david w nassif executive vice president  chief financial officer at steadymed ltd niles a fleischer general managerisraeli region at steadymed therapeutics inc michael burdick senior vice president regulatory affairs at versartis inc ella tenenbaumkoren vice presidentdrug product development at steadymed therapeutics inc gideon kahana chief executive officer at aespironics ltd amir genosar chief executive officer at aktivax inc carl hicks jr vice president pulmonary hypertension patient advocacy  community relationssteadymed therapeutics ltd at steadymed ltd see  more listings with relsci professional start my free trial ➤ see  more paths to peter d noymer peter d noymer you connections via relationship science peter d noymer sync your contacts to see how you can connect with peter d noymer start my free trial ➤ see more educational background   massachusetts institute of technology massachusetts institute of technology mit is a private research university located in cambridge massachusetts united states mit has five schools and one college containing a total of  academic departments with a strong emphasis on scientific engineering and technological education and research founded in 8 in response to the increasing industrialization of the united states the institute used a polytechnic university model and stressed laboratory instruction mit was elected to the association of american universities in    princeton university princeton university is a vibrant community of scholarship and learning that stands in the nations service and in the service of all nations chartered in 7 princeton is the fourtholdest college in the united states princeton is an independent coeducational nondenominational institution that provides undergraduate and graduate instruction in the humanities social sciences natural sciences and engineering as a worldrenowned research university princeton seeks to achieve the highest levels of distinction in the discovery and transmission of knowledge and understanding at the same time princeton is distinctive among research universities in its commitment to undergraduate teaching today more than  faculty members instruct approximately  undergraduate students and  graduate students the universitys generous financial aid program ensures that talented students from all economic backgrounds can afford a princeton education career history chief technology officer executive vice presidentresearch  development   current steadymed therapeutics inc steadymed therapeutics inc develops drug delivery therapeutics devices the company was founded by amir genosar ian solomon and gideon kahana in 0 and is headquartered in san ramon ca executive vice president of research  development  chief technical officer   current steadymed ltd steadymed ltd engages in the research development and manufacture of pharmaceutical products through the patchpump technology its portfolio includes trevyent for pulmonary arterial hypertension and at home patient analgesia for postsurgical pains the company was founded on june  0 and is headquartered in rehovot israel vice president product research  development 0  prior alexza pharmaceuticals inc alexza pharmaceuticals inc is a pharmaceutical company which is focused on the research development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions its product candidates are az and az the company was founded by alejandro c zaffaroni on december   and is headquartered in mountain view ca directorsystems engineering   0 aradigm corp aradigm corp is a pharmaceutical company which focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists aradigm was founded in  and is headquartered in hayward ca professor prior carnegie mellon university carnegie mellon university challenges the curious and passionate to imagine and deliver work that matters a private global research university carnegie mellon stands among the worlds most renowned educational institutions and sets its own coursewith cuttingedge brain science pathbreaking performances innovative startups driverless cars big data big ambitions nobel and turing prizes handson learning and a whole lot of robots cmu doesnt imagine the future they create it other affiliations peter d noymer is affiliated with steadymed therapeutics inc steadymed ltd alexza pharmaceuticals inc aradigm corp carnegie mellon university youve reached your 0 free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ alexza pharmaceuticals inc promotes peter d noymer phd to vice president product rd employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       alexza pharmaceuticals inc alxa promotes peter d noymer phd to vice president product rd tweet 0 0 pm mountain view calif march  prnewswirefirstcall  alexza pharmaceuticals inc announced today that peter d noymer phd has been promoted to vice president product research  development in this new position he will have oversight responsibilities for device engineering product development and pharmaceutical development for alexzas technology programsdr noymer joined alexza in 0 and was most recently senior director product research  development from  to 0 dr noymer held various management positions at aradigm corporation developing drug delivery combination products for both inhalation and injection prior to joining aradigm he held an appointment as visiting assistant professor at carnegie mellon university as well as various engineering positions at general electric dr noymer received ms and phd degrees in mechanical engineering from mit and a bs degree in mechanical  aerospace engineering from princeton universitywe are very pleased to announce peters promotion and welcome him to our management team said james v cassella phd senior vice president research  development peter and the product rd team have made significant contributions to alexzas technology base and product pipeline and we look forward to leveraging his leadership and experience in product development as alexza moves rapidly toward commercialization of its productsabout alexza pharmaceuticals incalexza pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel proprietary products for the treatment of acute and intermittent conditions the companys technology the staccator system vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation the drug is quickly absorbed through the lungs into the bloodstream providing speed of therapeutic onset that is comparable to intravenous administration but with greater ease patient comfort and convenience alexzas lead program is az staccato loxapine and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients alexza has completed and announced positive results from both of its az phase  clinical trials and is projecting a new drug application submission in early 0 the company has completed an endofphase  meeting with the fda for az staccato prochlorperazine and it has advanced az0 staccato loxapine into phase b testing both product candidates being developed for the acute treatment of migraine headache az staccato alprazolam has completed phase  testing and a phase a proofofconcept clinical trial product candidates that have completed phase  testing are az staccato fentanyl for the treatment of breakthrough pain and az staccato zaleplon for the treatment of insomnia more information including this and past press releases from alexza is available online at wwwalexzacomsafe harbor statementthis press release includes forwardlooking statements regarding the development and potential commercialization of the companys product candidates any statement describing a product candidate or alexzas goals expectations or beliefs is a forwardlooking statement as defined in the private securities litigation reform act of  and should be considered an atrisk statement such statements are subject to certain risks and uncertainties particularly those inherent in the process of developing and commercializing drugs the companys forwardlooking statements also involve assumptions that if they prove incorrect would cause its results to differ materially from those expressed or implied by such forwardlooking statements these and other risks concerning alexzas business are described in additional detail in the companys annual report on form 0k for the year ended december   and the companys other periodic and current reports filed with the securities and exchange commission forwardlooking statements contained in this announcement are made as of this date and we undertake no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwisecontact thomas b king president  ceo of alexza pharmaceuticals inc7 tkingalexzacom web site httpwwwalexzacom read at biospacecom related news alexza pharmaceuticals inc alxa cuts jobs has sufficient cash till q 0 pearl therapeutics appoints perry karsen as chief executive officer endo pharmaceuticals endp and alexza pharmaceuticals inc alxa conclude research collaboration proteolix inc announces the appointment of john scarlett md president and ceo alexza pharmaceuticals inc alxa initiates az0 staccator loxapine phase b clinical trial in patients with migraine headaches genocea biosciences closes  million series a financing names vaccine veteran staph leavenworth bakali ceo alexza pharmaceuticals inc alxa says trial for acute agitation meets goal johnson  johnson jnj ceo declines merit raise alexza pharmaceuticals inc alxa completes enrollment in second phase  clinical trial with az staccator loxapine for acute agitation mylan inc myl announces transition of chief financial officer please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • alexza pharmaceuticals inc   • biotechpharma  personnel                 peter noymer  alexza pharmaceuticals  email vp product rd  alexzacom  phone 7   business card for peter noymer peter noymer vp product rd mountain view ca area alexza pharmaceuticals  stierlin ct mountain view ca 0 tel  7 wwwalexzacom last updated on 70   get contact info  its free and takes  seconds opt out or update this contact opt out update name update title update phone update email not at this company anymore about peter noymer peter noymer works as an vp product rd for alexza pharmaceuticals at mountain view ca the companys webpage is httpwwwalexzacom for email phone number and executive profiles for vp product rd and other executives of alexza pharmaceuticals at mountain view ca check alexza pharmaceuticals at joesdatacom not the peter noymer you are looking for do a quick search in our website and find other people named peter noymer peter noymers work history no information available peter noymers education no information available peter noymers coworkers as of july 7 7 peter noymer has  coworkers under the company name alexza pharmaceuticals at joesdatacom about alexza pharmaceuticals alexza pharmaceuticals inc alexza is a pharmaceutical company focused on the research development and commercialization of products for the acute treatment of central nervous system cns conditions alexzas product candidates are based on its technology the staccato system the staccato system vaporizes an excipientfree drug to form a condensation aerosol that when inhaled allows for systemic drug delivery as of december   the company had screened more than  drug compounds identifying approximately 0 drug compounds that demonstrate initial vaporization the companys product candidate is adasuve staccato loxapine the companys other product candidates in active development are az staccato zaleplon and staccato nicotine the companys product candidates no source sec reports company news  8delisting of securities of alexza pharmaceuticals inc from the nasdaq stock market alexza pharmaceuticals to be acquired by ferrer alexza to cancel  first quarter financial results earnings call people in the same industry jessica baronsdirector business developmentrho incraymond ursickchief regulatory officerbioenterprise corporationsamuel whitakerfounder and board membergreenphire llcdavid grahamvp program  alliance managementaveo oncology incart blumsenior directorbiomarin pharmaceutical inckevin mcdermottvp managed marketsdaiichi sankyo company inc about us privacy terms of use work for us contact us people directory a b c d e f g h i j k l m n o p q r s t u v w x y z company directory a b c d e f g h i j k l m n o p q r s t u v w x y z copyright  7 joesdatacom all rights reserved